Background--The aim of the present study was to estimate the impact of dehydroepiandrosterone sulfate (DHEAS) on the prognosis of patients with cardiovascular disease by performing a systematic review and meta-analysis.
D ehydroepiandrosterone (DHEA) and its sulphated ester (DHEAS), working as multifunctional steroids, 1 are mainly produced in the adrenal cortex and converted to testosterone and estradiol in target tissues via androgenconverting enzymes. 2 DHEA is also synthesized in brain from 17OH pregnenolone and skin. 3 It is suggested that DHEAS is a neuroactive steroid that would have a decisive role in the central nervous system, and some studies have established an association between DHEAS levels and degenerative disorders of the nervous system, including Addison's disease, Alzheimer's disease, depression, memory loss, and schizophrenia. 4 The concentrations of DHEAS are sex related and vary during life. 5 As both cortisol and DHEAS are synthesized within the adrenal cortex, and it is conceivable that their respective relative contributions to adrenal steroid output might define observed biological action. Furthermore, the cortisol to DHEAS ratio has been found to predict health outcomes better than the level of either hormone alone and in aging, 6 Alzheimer's disease, 7 metabolic syndrome, [8] [9] [10] and allcause mortality (ACM). [10] [11] [12] [13] By far, the strongest associations with the metabolic syndrome were observed in the cortisol/ DHEAS ratio by Phillips et al. 8 As DHEAS and cortisol have opposing effects on the innate immune system, while DHEAS enhances, cortisol suppresses, and the molar ratio of cortisol to DHEAS also increases with age, so it may be an important marker of glucocorticoid function. 14 
It
is not yet clear whether the physiological decline in DHEA represents a harmful deficiency resulting from aging and the occurrence of degenerative processes or an agerelated adaptation. Several studies have documented that DHEA and DHEAS might be implicated in a broad range of biological abnormalities including obesity, diabetes mellitus, osteoporosis, sexual dysfunction, cancer, and mental disorders, leading to speculation that a relative DHEAS deficiency may contribute to the development of common age-related diseases or diminished longevity. [15] [16] [17] [18] [19] Special interest in the role of DHEA dates back to the discovery of a relationship between a low serum concentration of DHEA and higher morbidity and mortality due to cardiovascular disease (CVD). [20] [21] [22] [23] These findings were not confirmed by a later study 24 and the issue remains controversial. Therefore, we performed a systematic review and meta-analysis to clarify the impact of DHEAS on the prognosis of patients with CVD.
Methods

Search Strategy
Literature searches were performed to identify all relevant and published studies focused on the prognostic value of DHEAS for patients with CVD. Two authors (T.-T.W. and Y.C.) independently searched electronic databases (PubMed, Embase, Web of Science, CNKI, and WanFang) updated on September 5, 2016, using "DHEAS," "mortality," "CV event," and their corresponding index words as keywords.
Inclusion and Exclusion Criteria
Inclusion criteria were the following: (1) cohort studies that evaluated the prognostic value of DHEAS for patients with CVD; (2) studies with a follow-up duration of more than 1 year; (3) studies that reported at least 1 of the following outcomes: ACM, cardiovascular events such as cardiovascular death, myocardial infarction, stroke, heart failure, and readmission; and (4) paper type: original prospective quantitative cohort study (ie, no review, commentary, case reports, editorial). Studies that met any of the following exclusion criteria were excluded: (1) animal or cell line studies; (2) duplicated publications; and (3) manuscripts published in languages other than English or Chinese. Disagreements were resolved by discussion and consensus.
Data Extraction
Data extraction and quality assessment were performed independently by 2 authors (T.-T.W. and Y.C.). The following data were extracted from eligible studies: names of the first authors, publication year, sources of participants, sample sizes, participants' characteristics, follow-up durations, end points with their corresponding hazard ratios (HRs), risk ratios, odds ratios, and 95% CIs, and the confounding factors adjusted for. The corresponding authors of the eligible studies were contacted for detailed information if the necessary data were not reported in the full text of the papers. If no valid data were achieved, then we will exclude this study. The Newcastle-Ottawa Scale, with minor modifications, was used to assess the quality of the included studies. Any disagreements were resolved by discussion with a third author (Y.Z.) who was blinded to the previous results.
Statistical Analysis
Results reported as count data were presented for ACM, fatal cardiovascular events, and nonfatal cardiovascular events. The results of the included studies were pooled and meta-analyses were carried out using fixed-or random-effects models. Statistical heterogeneity between studies was assessed using the chisquare test with significance set at P<0.10, and heterogeneity was quantified using the I 2 statistic. I 2 values represent the proportion of total variation attributable to heterogeneity rather than chance whereby 0% is no observed heterogeneity and 100% is maximal heterogeneity. Potential publication bias was evaluated by visual inspection of a funnel plot. A priori sensitivity analyses were defined to evaluate the stability of the pooled estimates and to examine changes in results after excluding specific studies. The subgroup analyses were preplanned for: length of followup, study design, sample size, ethnicity, sex, and DHEAS categories as quartiles. The authors had full access to the data and take responsibility for its integrity. All authors read and agreed to the manuscript as written.
End Point Definition
The explored end points in this meta-analysis are as follows: ACM; fatal cardiovascular events; nonfatal cardiovascular events; and fatal/nonfatal cardiovascular events.
Results
Summary of Eligible Studies
Based on our search criteria, we identified 637 potentially relevant articles. By scanning the titles and abstracts we excluded 541 articles. A total of 71 studies were excluded for the following reasons: 33 lacked any of our requisite data and 27 were not related to CVD or CVD outcomes. Eleven were excluded based on study design. Overall, 25 cohort studies, with a total of 92 489 CVD patients, were included in our systematic review. 12, 13, For each of these studies, we extracted items including year of publication, name of the first author, country of origin of the research group, sample number of studies included, design used in the studies, quality evaluation of the studies, follow-up time, confounder for adjustments, DHEAS concentration gradient, and end point.
Results of the meta-analysis on the main end point are expressed as HRs and 95% CIs.
A flowchart outlining our literature search is shown in Figure 1 . A summary of the characteristics of the eligible studies is given in Table 1 . Twenty-one of the included studies were prospective cohort studies, whereas 4 were retrospective studies. For quality assessment, 25 studies were eligible and ranked according to their sum scores (Table 1) , of which 21 studies were graded as "good" (scores >6) and 4 as "moderate" (scores ≤6) quality. estimates (HRs/odds ratios), regression coefficients, and 95% CIs. Eleven studies investigated the relationship between DHEAS and ACM, 6 investigated fatal cardiovascular events, and 7 investigated nonfatal cardiovascular events. The confounding factors adjusted for among the eligible studies varied, including age, smoking, systolic and diastolic blood pressure, hypertension, high-density lipoprotein cholesterol, total cholesterol, diabetes mellitus, BMI, high serum C-reactive protein, Apolipoprotein B to Apolipoprotein A1 ratio, and low testosterone.
Main Findings of Eligible Studies
DHEAS and Outcomes
DHEAS and ACM
There were 11 studies that reported positive associations between low DHEAS concentrations and ACM. Meta-analysis 
Subgroup Analysis
To explore possible sources of heterogeneity among the eligible studies, subgroup analysis was performed. As shown in Tables 3 through 5 , different set of variables seemed to have no apparent effect on pooled HRs. At the same time, we performed subgroup analysis according to sex (see Figure 5 ).
Publication Bias
The funnel plot ( Figure 6 ) for studies of DHEAS and ACM and fatal and nonfatal cardiovascular events shows reasonable symmetry at the top of the funnel plot and slight asymmetry at the bottom, suggesting some evidence of publication bias for small studies.
Discussion
In this meta-analysis, we found that CVD patients with lower DHEAS levels may have poorer prognosis than those with higher DHEAS levels. To the best of our knowledge, this is the first systematic review and meta-analysis to clarify the relationship between DHEAS and CVD outcomes. Our meta-analysis included all English-language and Chinese-language published studies up until September 5, 2016 , that compared CVD outcomes in patients with lower or higher concentration of DHEAS. Twenty-five published studies were selected according to specified inclusion criteria, for a total of 92 489 patients. Of note, a lower concentration of DHEAS was associated with a significantly increased risk of overall mortality when all studies were considered (risk ratio, 1.47; 95% CI, 1.38-1.56).
Sex hormones play a pivotal role in regulating body composition both in men and women. DHEAS as their precursor has been shown to have many biological effects, and the clinical significance of DHEA and DHEAS in CVD remains uncertain. Epidemiological studies demonstrate that the association between low DHEAS and all-cause disease or CVD mortality is conflicting. Most of the studies in men show a negative relationship between DHEAS level and mortality and CVD mobility. 20, 30, 31, 36, 39, 47, 48 Similar conclusions in postmenopausal women with low DHEAS levels have been reported and are associated with higher cardiovascular mortality. 27, 29 Conversely, no association was observed between DHEAS and mortality in several studies. [49] [50] [51] Our meta-analysis including 92 489 patients clarified the relationship between DHEAS and CVD prognosis, which indicated the adrenal androgen DHEA and its sulfate form DHEAS, may be markers of the aging process and potential longevity. 52 Much evidence has indicated that obesity, type 2 diabetes mellitus, and the metabolic syndrome in men are all characterized by a hypogonadotropic hypogonadism, strictly related to body fat mass. [53] [54] [55] [56] Corona et al 57 reported that DHEA supplementation was associated with a reduction of fat mass and a trend toward an increase in lean mass. Although these effects were small and can be accounted for by adjustment for DHEA-derived metabolites, it provides a new train of thought to prevent the occurrence of CVD and reduce the long-term risk of death.
The mechanisms of the effect of DHEA and DHEAS on health outcomes remain unclear. Although DHEAS does not directly interact with the glucocorticoid receptor, research suggests that it may act as a functional antagonist to the effects of glucocorticoids. [58] [59] [60] This counterbalancing action might explain the relationship between DHEAS level and health outcomes known to be affected by chronically elevated cortisol levels, such as heart disease, diabetes mellitus, and cognitive impairment. 61, 62 A direct role for DHEA in opposing atherosclerosis is suggested by its ability to facilitate fibrinolysis, 63, 64 inhibit platelet aggregation, and retard cell proliferation. 65 Previous pathological research elucidated that the zona reticularis, which is responsible for DHEA production, is highly susceptibility to vascular damage. 66 Given these findings, DHEAS might reflect underlying vascular disease manifesting as endocrine dysfunction.
Study Limitations
Limitations of the present meta-analysis are essentially associated with the overall weakness of the studies reviewed, including the small size of the studies, the low statistical power, the often unreliable analytical methods for steroid detection, the different evaluation of confounding factors in the different studies such as sex, age, smoking, diabetes mellitus, metabolic syndrome, hypertension, obesity, dyslipidemia, and thyroid disease; the variation of aldosterone values; the treatments with corticosteroids or hypertension or menopause in women; the use of aldosteronereceptor blockers, different kinds of diuretics and other drugs that affect DHEAS level. At last, the differences in the clinical end points or populations analyzed. There is still a lack of basic understanding of the biological effects of DHEA and DHEAS and further data in men and in women from prospective studies including better assessment of covariates, and randomized trials are urgently needed.
Conclusions
The results of the present meta-analysis indicate that DHEAS is a poor prognostic marker for patients with CVD. Further studies are needed to uncover the potential mechanisms between low DHEAS level and poor prognosis in CVD patients.
Sources of Funding
This work was supported financially by the National Natural Science Foundation of China (81560070).
Disclosures
None.
